

Noxafil® (posaconazole) - First-time generic

- On June 29, 2023, <u>Par launched</u> an <u>AB-rated</u> generic version of Merck's <u>Noxafil (posaconazole)</u> injection.
- Noxafil injection is approved for treatment of invasive aspergillosis and prophylaxis of invasive Aspergillus and Candida infections.
 - The generic posaconazole injection is only approved for the prophylaxis of invasive Aspergillus and Candida infections due to pediatric exclusivity.
- Posaconazole is also available generically as a delayed-release tablet and oral suspension.
 - The tablet and oral suspension carry the same indications as Noxafil injection. In addition, the oral suspension is approved for the treatment of oropharyngeal candidiasis.
- According to IQVIA[™], Noxafil injection sales were approximately \$25 million for the 12 months ended May 31, 2023.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.